This study generates the seven-immune-related-gene-signature (CD1B, CHRNA6, CLEC12B, CLEC17A, CLNK, INHA, and SLC14A2) model in LUAD and the eight-immune-related-gene-signature (C4BPB, FCAMR, GRAPL, MAP1LC3C, MGC2889, TRIM55, UGT1A1, and VIPR2) model in LUSC, which can not only predict survival outcome but also reflect the immune status of lung cancers. This evidence concerns the gene CLEC17A and lung carcinoma.